Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by AngelaLon Jul 20, 2021 7:07pm

223 Views

Post# 33579345

Covid surging, vaccines failing after 6 months

Israel reported the shocking news yesterday that antibodies collapse 6 months after Pfizer vaccination! 60% reduction in ability to prevent severe disease. And this is to the older strain. Efficacy against the delta strain is worse. Vaccine-related complications also reported to be soaring due to the injury from the spike protein they produce. Vaccines will not be the answer. We need safe and effective drugs to tackle COVID. R-107 is tailor-made for this. Bad news for all of us about Covid returning but great news for Claritas shareholders.

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo